drug_type
RELEVANT_DRUG
intervention_type
Biologic (bispecific T‑cell–engaging antibody)
drug_description
An intraperitoneal recombinant human–mouse chimeric bispecific T‑cell–engaging antibody (anti‑EpCAM × anti‑CD3) that binds EpCAM on tumor cells and CD3 on T cells to activate TCR/CD3 signaling and redirect cytotoxic T‑cell killing of EpCAM‑positive tumor cells for control of peritoneal tumor burden and ascites.
nci_thesaurus_concept_id
C178327
nci_thesaurus_definition
A human-mouse chimeric bispecific antibody directed against both CD3 and epithelial cell adhesion molecule (EpCAM), with potential immunomodulating and antineoplastic activities. Upon administration, anti-EpCAM/anti-CD3 bispecific antibody M701 binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and EpCAM on EpCAM-expressing tumor cells. This activates and redirects CTLs to EpCAM-expressing tumor cells, which results in the CTL-mediated cell death of EpCAM-expressing tumor cells. EpCAM, a cell surface protein upregulated on many tumor cell types, promotes the proliferation, migration and invasiveness of tumor cells.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intraperitoneal
drug_mechanism_of_action
Bispecific antibody that binds EpCAM on tumor cells and CD3 on T cells, bringing them into proximity to activate TCR/CD3 signaling and redirect cytotoxic T-cell killing (perforin/granzyme and cytokine release) of EpCAM-positive tumor cells.
drug_name
M701
nct_id_drug_ref
NCT06432296